AMTI — Applied Molecular Transport. Share Price
- $11.01m
- -$7.10m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 0.68 | ||
Price to Tang. Book | 0.68 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | n/a | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -471.23% | ||
Return on Equity | -158.05% | ||
Operating Margin | n/a |
Financial Summary
Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | 50 | n/a | n/a |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company. The Company is leveraging its technology platform to design and develop a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The Company’s pipeline includes AMT-101, and AMT-126. AMT-101 is a gastrointestinal-selective oral fusion of interleukin 10 (IL-10) and its proprietary carrier molecule that has been designed for active transport across the intestinal epithelium (IE) barrier into local gastrointestinal (GI) tissue. AMT-126 is a GI-selective oral fusion of interleukin 22 (IL-22) and its proprietary carrier molecule presently in development for diseases related to IE barrier function defects. Its technology platform enables it to design and develop various oral biologic therapeutic modalities, such as peptides, proteins, full-length antibodies, antibody fragments, and ribonucleic acid (RNA) therapeutics with development-stage drugs.
Directors
- Graham Cooper CHM (51)
- Tahir Mahmood CEO (46)
- Randall Mrsny CFD (66)
- Shawn Cross CFO (53)
- Brandon Hants SVF (44)
- Derek Maclean SVP (54)
- Chuck Olson SVP (63)
- Douglas Rich CTO (52)
- Andy Whitney VPR (59)
- Elizabeth Bhatt OTH (53)
- Bittoo Kanwar OTH (45)
- Helen Kim LED (58)
- Holly Schachner DRC
- David Lamond IND (46)
- John Smither IND (67)
- Aaron VanDevender IND (40)
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- November 21st, 2016
- Public Since
- June 5th, 2020
- No. of Shareholders
- 10
- No. of Employees
- 79
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market
- Shares in Issue
- 41,848,990

- Address
- 450 East Jamie Court, WILMINGTON, 19801
- Web
- https://www.appliedmt.com/company/
- Phone
- +1 6503920420
- Auditors
- Deloitte & Touche LLP
Upcoming Events for AMTI
Q1 2024 Applied Molecular Transport Inc. Earnings Release
Applied Molecular Transport Inc. Annual Shareholders Meeting
Similar to AMTI
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
As of Today at 06:02 UTC, shares in Applied Molecular Transport. are trading at $0.26. This share price information is delayed by 15 minutes.
Shares in Applied Molecular Transport. last closed at $0.26 and the price had moved by -39.54% over the past 365 days. In terms of relative price strength the Applied Molecular Transport. share price has underperformed the S&P500 Index by -51.33% over the past year.
The overall consensus recommendation for Applied Molecular Transport. is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreApplied Molecular Transport. does not currently pay a dividend.
Applied Molecular Transport. does not currently pay a dividend.
Applied Molecular Transport. does not currently pay a dividend.
To buy shares in Applied Molecular Transport. you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.26, shares in Applied Molecular Transport. had a market capitalisation of $11.01m.
Here are the trading details for Applied Molecular Transport.:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: AMTI
Based on an overall assessment of its quality, value and momentum Applied Molecular Transport. is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Applied Molecular Transport. is $1.00. That is 280.23% above the last closing price of $0.26.
Analysts covering Applied Molecular Transport. currently have a consensus Earnings Per Share (EPS) forecast of -$0.95 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Applied Molecular Transport.. Over the past six months, its share price has underperformed the S&P500 Index by -12.85%.
As of the last closing price of $0.26, shares in Applied Molecular Transport. were trading +4.13% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Applied Molecular Transport. PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.26.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Applied Molecular Transport.'s management team is headed by:
- Graham Cooper - CHM
- Tahir Mahmood - CEO
- Randall Mrsny - CFD
- Shawn Cross - CFO
- Brandon Hants - SVF
- Derek Maclean - SVP
- Chuck Olson - SVP
- Douglas Rich - CTO
- Andy Whitney - VPR
- Elizabeth Bhatt - OTH
- Bittoo Kanwar - OTH
- Helen Kim - LED
- Holly Schachner - DRC
- David Lamond - IND
- John Smither - IND
- Aaron VanDevender - IND